Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference46 articles.
1. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019
2. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States;Mougalian;Cancer,2015
3. Neoadjuvant therapy as a platform for drug development and approval in breast cancer;Bardia;Clin Cancer Res,2013
4. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657);Campbell;Breast Cancer Res Treat,2017
5. Validation of residual proliferative cancer burden as a predictor of long-term outcome following neoadjuvant chemotherapy in patients with hormone receptor-positive/human epidermal growth receptor 2-negative breast cancer;Miglietta;Oncologist,2020
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics;Clinical Breast Cancer;2023-06
2. Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer;Pathology - Research and Practice;2023-05
3. Establishment and verification of a nomogram to predict tumor-specific mortality risk in triple-negative breast cancer: a competing risk model based on the SEER cohort study;Gland Surgery;2022-12
4. Pathological response of breast cancer of patients treated by neoadjuvant chemotherapy and correlation with survival. A perspective of real-world pathology;2022-10-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3